IZO:CC - Izotropic Creates Compensation Committee and Adopts Charter
(TheNewswire)
V ancouver , BC - TheNewswire - January 12, 2023 - Izotropic Corporation (“ Izotropic ” or the “ Company ”)(CSE: IZO ) (OTC: IZOZF )(FSE: 1R3 ), a medical device company commercializing IzoView, adedicated breast CT (computed tomography) imaging platform, for themore accurate detection and diagnosis of breast cancers, announcesthat it has created a compensation committee (the “CompensationCommittee” or the “Committee”) to review and makerecommendations to the Board of Directors on matters of compensation.
The Compensation Committee will assist in evaluatingand compensating named executive officers, executive officers, andconsultants; assist in identifying, assessing, and managing risksassociated with compensation policies; and identify and discuss withthe Board succession and resource planning risks, including ensuringthat executive compensation is adequate to attract, motivate andretain competent executive personnel; and ensure that executivecompensation is directly and materially related to operatingperformance and aligned with the short-term and long-term objectivesof the Company and its shareholders.
The Board has adopted a Compensation Committee Charterdetailing the roles and responsibilities of the Committee,composition, meeting framework, resources and authority, andundertakings in order to carry out its oversight capabilities.
The Compensation Committee is comprised of threeappointed members: Mr. Ali Sodagar, Mr. Ralph Proceviat, and Mr. AlexTokman.
ON BEHALF OF THE BOARD
Investor Relations Contact:
Mr. James Berard
Email: info@izocorp.com
Toll Free: 1-833-IZOCORP ext.1
Media Inquiries Contact:
Ms. Jaclyn Thast
Email: jaclyn@izocorp.com
Toll Free: 1-833-IZOCORP ext.3
About Izotropic Corporation
Izotropic Corporation is the only publicly tradedcompany commercializing a dedicated breast CT imaging platform,IzoView, for the more accurate detection and diagnosis of breastcancers. To expedite patient and provider access to IzoView,Izotropic's initial clinical study intends to demonstrate superiorperformance of diagnostic breast CT imaging over diagnosticmammography procedures. In follow-on clinical studies, Izotropic intends to validate platform applications,including breast screening in radiology, treatment planning andmonitoring in surgical oncology, and breast reconstruction and implantmonitoring in plastic and reconstructive surgery.
More information about Izotropic Corporation can befound on its website at izocorp.com and by reviewing its profile on SEDAR at sedar.com.
Forward-Looking Statements
This document may contain statements that are"Forward-Looking Statements," which are based upon thecurrent estimates, assumptions, projections, and expectations of theCompany's management, business, and its knowledge of the relevantmarket and economic environment in which it operates. The Company hastried, where possible, to identify suchinformation and statements by using words such as"anticipate," "believe," "envision,""estimate," "expect," "intend,""may," "plan," "predict,""project," "target," "potential,""will," "would," "could,""should," "continue," "contemplate" andother similar expressions and derivations thereof in connection withany discussion of future events, trends or prospects or futureoperating or financial performance, although not all forward-lookingstatements contain these identifying words.
These statements are not guarantees of performance andinvolve risks, including those related to capital requirements anduncertainties that are difficult to control or predict, and as such,they may cause future results of the Company's activity to differsignificantly from the content and implications of such statements.Forward-Looking Statements are pertinent only as of the date on whichthey are made, and the Company undertakes no obligation to update orrevise any Forward-Looking Statements to reflect new information orthe occurrence of future events or circumstances unless otherwiserequired to do so by law. Neither the Company nor its shareholders,officers, and consultants shall be liable for any action and theresults of any action taken by any person based on the informationcontained herein, including, without limitation the purchase or saleof Company securities. Nothing in this document should be deemed to bemedical or other advice of any kind. All images are for illustrativepurposes only. IzoView is not yet approved for sale.
Copyright (c) 2023 TheNewswire - All rights reserved.